MarginsXMarginsX
Home › Markets › Health Care › XBIO

Xenetic Biosciences Inc. (XBIO)

XBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.49
-10.24% on the day
Market cap
$3.5M
Nano cap
Revenue · 2025
$3.0M
+19.0% on 2024
Net income · 2025
-$2.7M
-90.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/0001683168-26-001737-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerXBIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001534525
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$3.0M
Net income-$2.7M
Operating income-$2.8M
Net margin-90.1%
Operating margin-95.2%
Revenue growth+19.0%
Cash$7.9M
Total assets$8.4M
P/E (computed)Net income was not positive
P/S (computed)1.2×

Warning signs

Cash runway
30.1 months
$5.8M cash at September 30, 2026
Share count, 1 year
+2.3%
2025-11-07 to 2026-11-06 · +52.1% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Going Concern and Management's Plan Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued."
10-Q 2026-11-12
Cash and burn$5.8M cash; operating cash flow -$579K a quarter.Report 2026-09-30
Shares outstanding2,343,181 (2026-11-06); 2,291,056 a year earlier; 1,540,684 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Hartford, Connecticut, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$725K-$1.7M-$662K$5.8MNo debt tags$3.0M10-Q 2026-11-12
Q2 2026
2026-06-30
$661K-$930K-$875K$6.5MNo debt tags$3.3M10-Q 2026-08-06
Q1 2026
2026-03-31
$807K-$456K-$536K$7.3MNo debt tags$3.2M10-Q 2026-05-12
Q4 2025
2025-12-31
$766K-$579K-$243K$7.9MNo debt tags$3.0M10-K 2026-03-12
Q3 2025
2025-09-30
$1.0M-$510K-$658K$4.1MNo debt tags$2.9M10-Q 2026-11-12
Q2 2025
2025-06-30
$590K-$689K-$384K$4.8MNo debt tags$2.4M10-Q 2026-08-06
Q1 2025
2025-03-31
$593K-$903K-$1.0M$5.2MNo debt tags$2.6M10-Q 2026-05-12
Q4 2024
2024-12-31
$649K-$1.1M-$674K$6.2MNo debt tags$2.5M10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52025-10-14
Latest annual report
FORM 10-K FOR DEC 2025 AMENDMENT 1
10-K/A2026-04-24
Latest quarterly / interim
FORM 10-Q FOR SEP 2026
10-Q2026-11-12
Latest current report
CURRENT REPORT
8-K2026-11-13
Latest proxyDEFA14A2026-11-13

Source: SEC EDGAR submissions feed, 488 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-11.3%
1 month-21.0%
3 months-49.5%
Year to date-23.5%
1 year-35.4%
From 52-week high-64.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SILOSilo Pharma Inc.$1.57-14.40%$3.4M
MDCXMedicus Pharma Ltd. Common Stock$1.69-13.33%$3.2M
XTLBXTL Biopharmaceuticals Ltd.$1.54-3.75%$3.8M
AZTRAzitra Inc$0.6270+3.06%$3.8M
RDHLRedhill Biopharma Ltd.$0.3605-3.87%$3.2M
GELSGelteq Limited$0.3589-5.63%$3.8M
IMNNImunon Inc.$0.5940-5.56%$3.9M
APUSApimeds Pharmaceuticals US Inc.$2.04-8.52%$3.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier